Sutro Biopharma Dirección
Dirección controles de criterios 2/4
El CEO de Sutro Biopharma es Bill Newell , nombrado en Jan 2009, tiene una permanencia de 15.83 años. compensación anual total es $2.13M, compuesta por 32.2% salario y 67.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.41% de las acciones de la empresa, por valor de $851.92K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 5.4 años, respectivamente.
Información clave
Bill Newell
Chief Executive Officer (CEO)
US$2.1m
Compensación total
| Porcentaje del salario del CEO | 32.2% |
| Permanencia del CEO | 15.8yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
Oct 11
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sep 23There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Aug 24Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Aug 22Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | US$2m | US$687k | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$3m | US$663k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$6m | US$625k | -US$106m |
| Sep 30 2021 | n/a | n/a | -US$127m |
| Jun 30 2021 | n/a | n/a | -US$79m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$554k | -US$32m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$497k | -US$56m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$9m | US$482k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$30m |
| Dec 31 2017 | US$703k | US$468k | -US$20m |
Compensación vs. Mercado: La compensación total de Bill($USD2.13M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.46M).
Compensación vs. Ingresos: La compensación de Bill ha sido consistente con los resultados de la empresa en el último año.
CEO
Bill Newell (66 yo)
15.8yrs
Permanencia
US$2,129,980
Compensación
Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 15.8yrs | US$2.13m | 0.41% $ 851.9k | |
| Chief Scientific Officer | 1.2yrs | US$1.63m | 0.029% $ 61.0k | |
| Chief Medical Officer | 1.8yrs | US$2.34m | 0.030% $ 61.7k | |
| President & COO | less than a year | US$1.43m | 0.066% $ 137.3k | |
| Founder | no data | sin datos | sin datos | |
| CFO & Secretary | 11.8yrs | US$2.08m | 0.13% $ 270.1k | |
| Chief Technical Operations Officer | 1.5yrs | sin datos | 0.038% $ 80.3k | |
| General Counsel | 3.7yrs | sin datos | sin datos | |
| Chief People & Communications Officer | 16.8yrs | US$1.30m | 0.10% $ 210.8k | |
| Chief Business Development Officer | less than a year | sin datos | sin datos | |
| Vice President & Controller | no data | sin datos | sin datos |
1.8yrs
Permanencia media
62yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de STRO no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 15.8yrs | US$2.13m | 0.41% $ 851.9k | |
| Independent Chair of the Board | 5.4yrs | US$173.11k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$138.11k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$138.11k | 0.068% $ 142.5k | |
| Independent Director | 15.3yrs | US$140.11k | 0.027% $ 56.8k | |
| Member of Scientific Advisory Board | 1.8yrs | US$1.53m | 0.12% $ 253.9k | |
| Chair of the Scientific Advisory Board | 4.5yrs | sin datos | sin datos | |
| Independent Director | 6.3yrs | US$133.11k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$152.11k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Clinical Advisory Board | 4.5yrs | sin datos | sin datos | |
| Independent Director | 3yrs | US$150.28k | 0% $ 0 |
5.4yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de STRO se considera experimentada (5.4 años de antigüedad promedio).